Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | GCKR | Q14397 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RUVBL2 | Q9Y230 | 1/20 | 0.30 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 2/20 | 0.30 |
| ▸ | PPARD | Q03181 | 2/20 | 0.30 |
| ▸ | PPARA | Q07869 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063315 | 0.99 | CNR1 (0.34) | CNR1GCKRLMNASMN1; SMN2RUVBL2 | |
| SCHEMBL3055178 | 0.86 | CNR1 (0.43) | CNR1SMN1; SMN2 | |
| SCHEMBL3054079 | 0.85 | CNR1 (0.37) | CNR1LMNASMN1; SMN2RUVBL2RUVBL1 | |
| SCHEMBL3055355 | 0.85 | CNR1 (0.43) | CNR1LMNASMN1; SMN2 | |
| SCHEMBL3064293 | 0.84 | CNR1 (0.38) | CNR1GCKRLMNASMN1; SMN2RUVBL2 | |
| SCHEMBL3054607 | 0.83 | CNR1 (0.39) | CNR1LMNASMN1; SMN2RUVBL2RUVBL1 | |
| SCHEMBL3055326 | 0.82 | CNR1 (0.35) | CNR1GCKRLMNASMN1; SMN2 | |
| SCHEMBL3046093 | 0.81 | CNR1 (0.38) | CNR1LMNASMN1; SMN2RUVBL2RUVBL1 | |
| SCHEMBL3055030 | 0.81 | MMP1 (0.35) | LMNASMN1; SMN2 | |
| SCHEMBL3050123 | 0.81 | CNR1 (0.41) | CNR1LMNASMN1; SMN2RUVBL2RUVBL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CNR1 3782/4885GCKR 4505/4885LMNA 1113/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CNR1 3782/4885GCKR 4505/4885LMNA 1113/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CNR1 3782/4885GCKR 4505/4885LMNA 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.